Therapy of Refractory AML with Del(5q) with Low-Dose Lenalidomide
| Autor: | Elena Goryunova, Larisa Girshova, Ekaterina Romanova, Yulia Alexeeva, Tatiana Nikulina, Dmitry Motorin, Andrey Zaritskey |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Daunorubicin
business.industry Immunology Chronic myelomonocytic leukemia Cell Biology Hematology CD38 medicine.disease Biochemistry Leukemia medicine.anatomical_structure hemic and lymphatic diseases medicine Cytarabine Cancer research FLAG (chemotherapy) Bone marrow business medicine.drug Lenalidomide |
| Zdroj: | Blood. 118:4286-4286 |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | Abstract 4286 AML M-4 with >30% bone marrow myeloblasts was detected in 63 y old woman 2 mo after a diagnosis of chronic myelomonocytic leukemia (CMMLgrade 2). Cytogenetics showed 46, XX, del(5)(q12 q14) (N=4)/46, XX (N=18). Immune-phenotyping showed CD34+ CD117+ CD13+ CD33+ CD38+ HLADR+ CD2+. Leukemia cells were negative for inv (16), BCR/ABL, NPM, TEL/AML1, MLL/AF4, PML/RARA and AML1/ETO. She was RBC-transfusion-dependent. Therapy with cytarabine and daunorubicin and later with FLAG was ineffective and bone marrow myeloblasts increased to >70% with severe granulocytopenia and infection including pulmonary aspergillosis. She then received lenalidomide, 10 mg/d for 21 d every 4 w Bone marrow myeloblasts decreased to about 20% and granulocytopenia resolved. RBC-transfusion–dependence decreased. Cytogenetic and FISH-testing showed no detectable cells with del(5). This has persisted for 5 mo. Disclosures: Off Label Use: Lenalidomide for the treatment of AML with 5q- deletion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|